Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention by Vergara-Jimenez, Jennifer & Tricoci, Pierluigi
© 2010 Vergara-Jimenez and Tricoci, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2010:6 39–45
Vascular Health and Risk Management
39
R e V i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Safety and efficacy of abciximab as an adjunct 
to percutaneous coronary intervention
Jennifer Vergara-Jimenez 
Pierluigi Tricoci
Department of Medicine-Cardiology, 
Duke Clinical Research institute, 
Durham, North Carolina, USA
Correspondence: Pierluigi   Tricoci 
Duke Clinical Research institute, 
2400 Pratt Street, Room 0311,   Terrace 
Level, Durham, NC 27705, USA 
email trico001@mc.duke.edu
Abstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the 
setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied 
have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation 
myocardial infarction, and elective PCI. This large amount of information provides a clear 
efficacy and safety profile of the drug, although a few questions on the use of abciximab still 
exist, particularly on its use and preference in the setting of newer antiplatelet and antithrombotic 
medications. In this article we review the most relevant data from randomized clinical trials 
with abciximab in patients undergoing PCI and discuss the recent guideline recommendation 
on use during PCI.
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Coronary artery disease affects about 16 million men and women in the United States, 
causing approximately 450,000 deaths every year.1,2
Percutaneous coronary intervention (PCI) is one of the current treatment options 
for coronary artery disease. The American Heart Association in their Heart Disease 
and Stroke statistics 2008 reports that 1,270,000 angioplasties were performed in the 
United States during 2005.3
Antiplatelet therapy is the mainstay of medical management during PCI. The 
principal objectives of antiplatelet therapy are to maintain the stent patency, reduce 
the risk of stent thrombosis, reduce the risk of periprocedural complications, and 
ultimately reduce the risk of important ischemic events such as death and myocardial 
infarction. Platelets are activated though a variety of agonists each acting on specific 
pathways. These all lead to a final common pathway which is the activation of the 
glycoprotein (GP) IIb/IIIa. Activated GP IIb/IIIa links to fibrinogen, and produces 
platelet aggregation (Figures 1 and 2).
GP IIb/IIIa inhibitors are a class of medication that act by blocking the GP IIb/IIIa 
receptor. This class has been extensively studied in patients with acute coronary 
syndromes (ACS) and those undergoing PCI. GP IIb/IIIa inhibitors currently avail-
able are intravenous agents: abciximab, eptifibatide, and tirofiban. Eptifibatide and 
tirofiban are small-molecule GP IIb/IIIa inhibitors, while abciximab is a humanized 
murine monoclonal antibody fragment (Figure 3).
Abciximab binds with high-affinity the GP IIb/IIIa receptor, resulting in slow 
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half-life of the drug. Thus, the platelet inhibition with 
abciximab lasts approximately 48 hours after the drug is 
discontinued.
Clinical trials of abciximab during 
elective PCI
Abciximab vs placebo
Abciximab was the first GP IIb/IIIa inhibitor studied in the 
setting of PCI, on top of aspirin and heparin. In the Evalu-
ation of 7E3 for the Prevention of Ischemic Complications 
(EPIC) trial of 2099 patients undergoing PCI who were felt 
at high risk of ischemic complication, patients who received 
abciximab (0.25 mg/kg bolus followed by 10 µg/min infusion 
for 12 hours) had a significant 35% reduction compared with 
placebo (12.8% vs 8.3%, P = 0.008) in the rate of the 30 days 
primary endpoint (a composite of death, nonfatal myocardial 
infarction, unplanned surgical revascularization, unplanned 
repeat percutaneous procedure, unplanned implantation of a 
coronary stent, or insertion of an intra-aortic balloon pump 
for refractory ischemia).4 No significant benefit was observed 
among patients receiving bolus alone. Patients receiving 
bolus and infusion of abciximab had an important increase in 
both the rate of major bleeding and transfusion, particularly 
CABG and vascular access site related bleeding.
The Evaluation in PTCA to Improve Long-Term Out-
come with Abciximab GP IIb/IIIa Blockade (EPILOG) 
study evaluated a lower-risk population (patients with acute 
myocardial infarction or unstable angina were excluded) and 
compared 3 arms, abciximab plus standard dose of heparin 
(100 U/kg bolus), abciximab plus moderate regimen of 
heparin (70 U/kg bolus), and placebo plus standard dose of 
heparin.5 The low-dose of heparin arm was introduced to 
reduce the rate of bleeding observed in the EPIC trial. The 
trial enrolled 2792 patients (of the 4800 planned) and was 
stopped after an interim analysis showed a 50% reduction 
in the risk of the primary efficacy endpoint (death from any 
cause, myocardial infarction, or urgent revascularization 
within 30 days) in the 2 groups treated with abciximab. 
The rate of primary endpoint was 11.7% in the placebo group 
compared with 5.2% in the abciximab with low-dose heparin 
group (hazard ratio [HR] 0.43, 95% confidence interval 
[CI] 0.30 to 0.60) and 5.4% in the abciximab with standard-
dose heparin group (HR 0.45, 95% CI 0.32 to 0.63). Major 
bleeding was lower in the abciximab plus low dose heparin 
group (2.0%) compared with patients in the abciximab 
plus standard-dose heparin group (3.5%) and placebo plus 
standard-dose heparin group (3.1%), although the differences 
were not statistically significant.
The benefit of abciximab in patients undergoing stent 
placement was evaluated in 2399 patients enrolled in the 
Evaluation of Platelet Inhibition in STENTing (EPISTENT) 
trial.6 Patients were randomized to receive stent plus 
abciximab, stent plus placebo, and balloon angioplasty plus 
abciximab. The primary endpoint was a composite of death, 
myocardial infarction, or need for urgent revascularization 
within 30 days. In patients receiving a stent there was a 52% 
reduction in the risk of the primary endpoint in the abciximab 
group compared with placebo (5.3% vs 10.8%; HR 0.48, 
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Figure 1 Mechanisms involved in platelet aggregation.
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95% CI 0.33 to 0.69). Patients in the balloon angioplasty 
plus abciximab group also had a lower rate of the primary 
endpoint than the stent plus placebo group (6.9% vs 10.8%; 
HR 0.63 95% CI 0.45 to 0.88). Major bleeding occurred 
in 2.2% of patients in the stent plus placebo group, 1.5% 
in the stent plus abciximab group, and 1.4% in the balloon 
angioplasty plus abciximab; these differences were not 
statistically significant.
Abciximab vs other GP iib/iiia inhibitors
There is only one large phase 3 trial comparing in a “head-
to-head” fashion two different GP IIb/IIIa inhibitors. The Do 
Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET) 
compared abciximab and tirofiban to demonstrate nonin-
feriority of tirofiban.7 A total of 5308 patients undergoing 
PCI were assigned to receive either abciximab (0.25 mg/kg 
bolus, followed by a 12 hours infusion of 0.125 µg/kg/min) 
or tirofiban (10 µg/kg bolus, followed by 18 to 24 hours 
infusion of 0.15 µg/kg/min). All patients received heparin 
and aspirin and, when possible, a loading dose of clopidogrel. 
The primary endpoint occurred at a higher rate in the tirofi-
ban group compared to the abciximab group (7.6% vs 6.0%, 
HR, 1.26; one-sided 95% CI 1.51), which indicates that the 
2 drugs were not equivalent, and actually abciximab proved 
superior to tirofiban. The rate of major bleeding or transfu-
sion was similar in the 2 groups (0.9% vs 0.7%). Some has 
argued that the tirofiban was not optimally dosed in the trial, 
because, as shown in the Comparison Of Measurements of 
Platelet aggregation with Aggrastat, Reopro, and Eptifibatide 
(COMPARE) trial, the dosing regimen of tirofiban used pro-
duced less platelet aggregation inhibition at 15 to 30 minutes 
compared with abciximab or eptifibatide.8
Abciximab in addition to clopidogrel
The question of whether GP IIb/IIIa inhibitors are needed in 
the PCI setting with pretreatment with a high loading dose 
of clopidogrel is under debate, and not fully clarified. The 
question was addressed in the Intracoronary Stenting and 
Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment (ISAR-REACT) trial which included 2159 patients 
undergoing low-risk PCI.9 All patients were pretreated with 
600 mg of clopidogrel loading dose at least 2 hours before 
the intervention. Patients were then randomized to receive 
abciximab or placebo. The rate of the primary endpoint 
was similar in the two groups (4% vs 4%; relative risk 
[RR] 1.05; 95% CI 0.69 to 1.59), as was the rate of major 
bleeding (1% vs 1%). The ISAR-Is Abciximab a Superior 
Way to Eliminate Elevated Thrombotic Risk in Diabetics 
(SWEET) trial addressed a similar question in a population 
of 701 diabetes patients who underwent elective PCI after 
receiving a 600 mg loading of clopidogrel.10 The incidence 
of death and myocardial infarction at 1 year was similar in 
the abciximab and placebo group (8.3% vs 8.6%; RR 0.97, 
95% CI 0.58 to 1.62).
None of the two previous studies evaluated high-risk ACS 
patients undergoing PCI. For this reason the ISAR-REACT2 
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was necessary. This protocol included 2022 patients with 
cardiovascular high risk who received pretreatment with 
clopidogrel 600 mg in the 2 hours before PCI and also 
aspirin 500 mg po or iv. When they entered the catheteriza-
tion lab, the patients was randomly assigned to 1) abciximab 
0.25 mg/kg bolus, followed by a 12-hour infusion of 0.125 µg/
kg/min [max dose 10 µg/min] plus heparin 70 U/kg, or 2) 
placebo bolus and 12-hour infusion, plus heparin bolus, 140 
U/kg. The primary composite endpoint (death, myocardial 
infarction, or urgent target vessel revascularization (TVR) at 
30 days) was reduced in patients in abciximab group.11
Abciximab vs bivalirudin
The Randomized Evaluation in PCI Linking Bivalirudin 
to Reduced Clinical Events (REPLACE)-2 trial evaluated 
6010 patients undergoing elective or urgent PCI.12 Patients 
were randomized to receive heparin plus a GP IIb/IIIa inhibitor 
(abciximab or eptifibatide) or bivalirudin alone (with provi-
sional use of GP IIb/IIIa inhibitors in case of complication 
during PCI). The trial aimed to establish the noninferiority 
of bivalirudin compared with heparin plus GP IIb/IIIa inhibi-
tors on the composite of 30-day death, myocardial infarction, 
urgent repeat revascularization, or in-hospital major bleeding 
(net clinical outcome). Forty-three percent of patients in the 
GP IIb/III inhibitor group received abciximab. The rate of the 
net clinical outcome was comparable in the 2 groups (10.0% 
vs 9.2% for heparin and bivalirudin groups, respectively; odds 
ratio [OR] 0.92, 95% CI 0.77 to 1.09). There was a modest 
nonsignificant excess of ischemic complication at 30 days in 
the bivalirudin group compared to the heparin group (7.6% 
vs 7.1%), whereas major bleeding (2.4% vs 4.1%; P  0.001) 
and transfusion (2.5% vs 1.7%; P = 0.02) were significantly 
higher in the heparin group.
Clinical trials of abciximab in patients 
with non-ST -segment elevation 
(NSTE) ACS undergoing PCI
Abciximab vs placebo
The Chimeric 7E3 Antiplatelet Therapy in Unstable angina 
Refractory to standard treatment (CAPTURE) trial addressed 
the efficacy and safety of abciximab in patients with refractory 
unstable angina, defined as recurrent ischemia despite therapy 
with heparin and nitrates, and the benefit of abciximab 
administered as pretreatment before the procedure.13 A total 
of 1265 patients were randomized after angiography to receive 
either abciximab or placebo for 18 to 24 hour before PCI, 
and 1 hour following the procedure. The primary endpoint 
was death, myocardial infarction, or urgent intervention for 
recurrent ischemia within 30 days. The rate of the primary 
endpoint was 11.3% in the abciximab group and 15.9% in the 
placebo group (P = 0.012). Major bleeding was increased in 
the abciximab group (3.8% vs 1.9%; P = 0.043).
A trial of abciximab in patients with NSTE ACS was 
also performed in patients not scheduled to undergo an 
early revascularization, the GUSTO IV-ACS. In this trial 
abciximab infusion (24 hours or 48 hours) did not show any 
benefit in reduction of death or myocardial infarction.14 Thus, 
in patients with NSTE ACS the use of abciximab is reserved 
only for those undergoing PCI, with the administration start-
ing downstream in the cardiac catheterization.15
Alternative abciximab modes of use
The use of GP IIb/IIIa inhibitor in patients undergoing PCI 
through a radial vascular access is a potentially appealing 
strategy, because a radial approach is associated with less 
periprocedural bleeding complications than the traditional 
femoral approach, and therefore the use of this class of 
agent may have its benefit vs risk ratio maximized in this 
setting. The Early Discharge After Transradial Stenting of 
Coronary Arteries (EASY) study compared a single bolus 
of abciximab with discharge the same day with standard 
bolus and overnight infusion in 1005 patients undergoing 
transradial PCI.16 The authors concluded that a single bolus 
is noninferior to the traditional administration regimen in pre-
venting the composite of death, myocardial infarction, repeat 
hospitalization, major bleeding, access site complication, and 
severe thrombocytopenia.
Another strategy of abciximab administration that has 
been studied is the intracoronary use. In a trial of 154 patients 
undergoing primary PCI, patients were randomized to receive 
either intracoronary bolus or intravenous bolus, both followed 
by standard intravenous infusion.17 The primary endpoint 
was the infarct size and extent of microvascular obstruction 
evaluated with delayed-enhancement MRI. The rationale of 
intracoronary bolus is to achieve a higher intracoronary con-
centration and by this mean coronary flow may be improved. 
In this study the intracoronary administration significantly 
reduced both the infarct size and microvascular obstruction. 
These results clearly need to be confirmed on a larger scale 
to address whether intracoronary revascularization improves 
clinical outcome.
Abciximab in addition to clopidogrel
The ISAR-REACT 2 evaluated whether abciximab was 
superior to placebo in NSTE ACS patients pretreated with Vascular Health and Risk Management 2010:6 43
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clopidogrel 600 mg loading dose prior to PCI. Among the 
2022 patients included in the trial, the abciximab group had 
25% reduction in the risk of death, myocardial infarction, or 
urgent target vessel revascularization (8.9% vs 11.9%; RR 
0.75, 95% CI 0.58 to 0.97).9 A subgroup analysis showed that 
only troponin-positive patients had a benefit from abciximab, 
a finding similar to that of other studies. The rate of major 
bleeding (1.4% vs 1.4%; RR 1.00, 95% CI 0.50 to 2.08) was 
similar in the 2 groups.
Abciximab vs bivalirudin
The randomized Acute Catheterization and Urgent Inter-
vention Strategy (ACUITY) trial evaluated 3 different 
strategies among 13,819 patients with NSTE ACS: heparin 
plus a GP IIb/IIIa inhibitor, bivalirudin plus a GP IIb/IIIa 
inhibitor, or bivalirudin alone.18 The primary objective of 
the trial was to establish noninferiority of the bivalirudin 
regimens, compared to heparin plus GP IIb/IIIa inhibitors 
on the primary net benefit endpoint of 30-day death, MI, 
unplanned revascularization for ischemia (composite isch-
emic endpoint) or major bleeding. A total of 7789 patients 
underwent PCI in the trial. The trial was open label and the 
decision of which GP IIb/IIIa inhibitor to use was left to 
the treating physician; in the group of patients who were 
randomized to receive a GP IIb/IIIa inhibitor abciximab was 
the drug of choice at the time of PCI in 17% of patients (the 
majority of patients received eptifibatide). Patients receiving 
bivalirudin plus GP IIb/IIIa inhibitor group and heparin plus 
GP IIb/IIIa inhibitor group had similar efficacy and safety 
outcomes. In the bivalirudin-alone group the rate of the net 
clinical outcome was significantly lower than in the heparin 
plus GP IIb/IIIa inhibitor group (10.1% vs 11.7%; RR 0.86, 
95% CI 0.77 to 0.97), which was entirely driven by a lower 
rate of bleeding (3.0% vs 5.7%; RR 0.53, 95% CI 0.43 to 
0.65). There was a nonsignificant numerical increase in 
the ischemic complications in the bivalirudin-alone group 
(7.8% vs 7.3%; RR 1.08, 95% CI 0.93 to 1.24) which did not 
exceed the prespecified 25% margin for noninferiority.
Trials of abciximab in patients with 
ST -segment elevation mycocardial 
infarction (STEMI) undergoing 
primary PCI
The Controlled Abciximab and Device Investigation to Lower 
Late Angioplasty Complication (CADILLAC) trial included 
2082 STEMI patients who received, in a factorial design, 
balloon angioplasty vs stenting, and abciximab or balloon 
angioplasty/stenting alone.19 The incidence of 6-month death, 
reinfarction, disabling stroke, and ischemia-driven TVR was 
increased in the balloon angioplasty alone (20.0%) compared 
with balloon angioplasty plus abciximab (16.5%), stenting 
alone (11.5%), and stenting plus abciximab (10.2%) groups, 
suggesting that abciximab did not provide a significant addi-
tional advantage in patients receiving a coronary stent.
In a meta-analysis of studies comparing abciximab with 
placebo in STEMI patients undergoing primary stenting, 
including 1101 patients a significant reduction in the risk of 
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death or reinfarction (19.0% vs 12.9%; RR 0.63, 95% CI 0.45 
to 0.89) and a reduction in mortality (14.3% vs 10.9%; RR 
0.70, 95% CI 0.48 to 1.00) was observed in patients treated 
with abciximab.20 The rates of major bleeding were 2.5% 
in the abciximab group and 2.0% in the placebo group.
The Facilitated Intervention with Enhanced Reperfusion 
Speed to Stop Events (FINESSE) study compared, in 2452 
STEMI patients undergoing primary PCI, 2 facilitated strategies 
(abciximab alone or combination of abciximab and reduced-
dose reteplase) with the use of abciximab in the catheterization 
lab.21 The primary endpoint was the composite of death, ven-
tricular fibrillation occurring 48 hours after randomization, 
cardiogenic shock, and congestive heart failure during the 
first 90 days after randomization. The primary endpoint was 
not statistically different in the 3 groups (9.8% of the patients 
in the combination-facilitated PCI group; 10.5% abciximab-
facilitated PCI group; and 10.7% in the primary-PCI group with 
downstream abciximab; P = 0.55). Thus, upstream treatments 
with abciximab in the setting of primary PCI did not differ with 
the use of the drug at the time of PCI.
The Harmonizing Outcomes with Revascularization and 
Stents in Acute Myocardial Infarction (HORIZONS-AMI) 
study was an open-label clinical trial comparing bivalirudin 
alone with heparin plus a GP IIb/IIIa inhibitor in patients with 
STEMI undergoing primary PCI.22 A total of 3602 patients 
was enrolled and abciximab was the agent selected in 52% 
of patients in the heparin plus GP IIb/IIIa inhibitor group. 
The two co-primary end points were major bleeding and a net 
clinical outcome including major bleeding or a major isch-
emic event within 30 days. Patients who received bivalirudin 
alone had a reduction in the net clinical outcome (9.2% vs 
12.1%; RR 0.76; 95% CI 0.63 to 0.92), entirely driven by 
a lower rate of major bleeding (4.9% vs 8.3%; RR 0.60, 
95% CI, 0.46 to 0.77). On the other hand patients in the 
bivalirudin group had an increased rate of stent thrombosis 
in the first 24 hours. Of note, bivalirudin alone resulted in a 
significant reduction of mortality at 30 days (2.1% vs 3.1%; 
RR 0.66, 95% CI 0.44 to 1.00), which the authors attributed 
to the reduction in bleeding.
The Multicentre Evaluation of Single High-Dose Bolus 
Tirofiban vs Abciximab With Sirolimus-Eluting Stent or 
Bare Metal Stent in Acute Myocardial Infarction (MUL-
TISTRATEGY) Trial, as a part of a factorial design, tried 
to assess whether high-dose bolus of tirofiban was nonin-
ferior to abciximab in inducing ST-segment resolution at 
90 minutes in 745 patients with STEMI treated with primary 
PCI.23 Patients were also randomized to receive a sirolimus-
eluting stent vs bare metal stent. ST-segment resolution 
occurred in 83.6% in the abciximab group and 85.3% in the 
tirofiban group, meeting the specified noninferiority criteria 
(RR 1.020; 97.5% CI 0.958 to 1.086). Ischemic and bleeding 
complication was similar in the 2 groups.
A high-dose bolus regimen of tirofiban in STEMI patients 
treated with primary PCI was also tested against abciximab 
in the Facilitated Angioplasty with Tirofiban or Abciximab 
(FATA) study, including 692 patients. Unlike the MULTI-
STRATEGY, the study failed to show a noninferiority, as 
specified in this trial, of tirofiban versus abciximab in the rate 
of ST-segment resolution at 90 minutes (67% vs 70% in the 
abciximab and tirofiban groups, respectively).24 Nonetheless 
the absolute difference between the 2 groups was comparable 
across the 2 trials.
Current PCI guidelines 
recommendation
Abciximab is one of the agents of choice recommended by 
current ACC/AHA guidelines in patients undergoing PCI.25 
The ACC/AHA/SCAI 2005 PCI practice guidelines recom-
mend (class 1, level of evidence A) the use of a GP IIb/IIIa 
inhibitors (abciximab, eptifibatide, or tirofiban) in patients 
with unstable angina (UA)/NSTEMI undergoing PCI but 
who are not pretreated with clopidogrel.26 In UA/NSTEMI 
patients who received clopidogrel the recommendation is 
less certain (class II, level of evidence B). The guidelines 
also recommend, as class II recommendation (level of 
evidence B), the use of early abciximab in patients with 
STEMI undergoing PCI, and the use of a GP IIb/IIIa inhibitor 
in patients undergoing elective PCI and stent.
Conclusion
Abciximab, as one of the most largely studied antiplatelet 
agents, currently represents a valuable therapeutic choice in 
the treatment of patients undergoing PCI for a broad spectrum 
of clinical indications.
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